Purpose: Fractionated peptide receptor radionuclide therapy (PRRT) with Lu-DOTATATE is increasingly applied as an effective treatment for patients with disseminated neuroendocrine tumors. In parallel to dose planning before external beam radiation therapy, dosimetry is also needed to optimize PRRT to the individual patient. Accordingly, absorbed doses to organs at risk need to be calculated during PRRT, based on serial measurements of radioactivity distribution utilizing SPECT/CT. The dosimetry should be based on as few measurements as possible, while still retaining reliable results. The main aim of the present work was to calculate the fractional contribution of the extrapolations of the curve fits for the absorbed dose calculations to the kidneys. The secondary aim was to study agreement between absorbed dose (AD) and the effective half-life (t) for the kidneys, estimated by means of measurements at one or two time points, in comparison to our current method employing three time points.
Methods: In 777 patients with disseminated neuroendocrine tumors undergoing PRRT, SPECT/CT over the abdomen was acquired at 1, 4, and 7 days after Lu-DOTATATE infusion. The absorbed dose to the kidneys was calculated from SPECT/CT radioactivity distribution data, and the t and fractional contributions of the extrapolations were estimated, utilizing data from one, two, and three time points, respectively.
Results: The fractional contributions from extrapolations before day 1 measurement and after day 7 measurement were approximately 26% and 11%, respectively. The mean differences in absorbed dose, based on one, two, and three time points were small, but with high method dependence for individual patients. The differences in estimated t were small when it was based on measurements at days 1 and 7, but high for days 1 and 4 time points.
Conclusion: When assessing simplifications of methods for calculation of the absorbed dose to the kidneys, it was of the uttermost importance to incorporate the fractional contribution for the extrapolations included in the reference method. Measurements at an early and a late time point were found most important. An intermediate measurement contributes with an idea of the goodness of the fit.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7726073 | PMC |
http://dx.doi.org/10.1186/s40658-020-00339-2 | DOI Listing |
Cureus
December 2024
Department of Diagnostic Imaging and Radiotherapy, Kulliyyah of Allied Health Sciences, International Islamic University Malaysia, Kuantan Campus, Kuantan, MYS.
In abdominal X-ray examinations, radiosensitive organs such as the gonads within or near the imaging region are at risk of radiation exposure. Minimizing the dose to these organs is crucial to reducing unnecessary radiation. This study utilized optically stimulated luminescence dosimeters (OSLDs) to measure the radiation dose to the male gonads at varying kilovoltage peak (kVp) settings while keeping the milliampere-seconds (mAs) constant across different radiographic projections.
View Article and Find Full Text PDFFront Oncol
January 2025
Department of Clinical Development, POINT Biopharma, a wholly owned subsidiary of Eli Lilly and Company, Indianapolis, IN, United States.
Introduction: SPLASH (NCT04647526) is a multicenter phase III trial evaluating the efficacy and safety of [Lu]Lu-PNT2002 radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC). This study leveraged a lead-in phase to assess tissue dosimetry and evaluate preliminary safety and efficacy, prior to expansion into a randomized phase. Here we report those results.
View Article and Find Full Text PDFDentomaxillofac Radiol
January 2025
Assist. Prof. Dr, Selcuk University Faculty of Medicine, Department of Radiation Oncology, Konya, 42130, Turkiye.
Objectives: Due to the increasing use of cone-beam computed tomography (CBCT) in dentistry and considering the effects of radiation on radiosensitive organs, the aim of this study was to investigate the effect of shielding on absorbed dose of eyes, thyroid and breasts in scans conducted with different parameters using two different fields of view (FOV).
Methods: Dose measurements were calculated on a tissue-equivalent female phantom by repeating each scanning parameter three times and placing at least two thermoluminescent dosimeters (TLD) on each organ, with the averages then taken. The same CBCT scans were performed in two different FOV with shielding including thyroid collar, radiation safety glasses and lead apron and without shielding.
Drug Des Devel Ther
January 2025
The First Affiliated Hospital of Wenzhou Medical University, Zhejiang, People's Republic of China.
Background: Givinostat, a potent histone deacetylase (HDAC) inhibitor, is promising for the treatment of relapsed leukemia and myeloma.
Purpose: This study aimed to develop and verify a quick assay for the measurement of givinostat concentration using ultra-performance liquid chromatography tandem mass spectrometry (UPLC-MS/MS) with eliglustat as the internal standard (IS), establishing a basic pharmacokinetic profile for its pre-clinical application and metabolic stability in vitro.
Methods: Sample preparation was performed via protein precipitation using acetonitrile.
J Pharm Sci
January 2025
Center of Clinical Pharmacology, the Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou 310009, China. Electronic address:
CZ1S injection is a novel, extended-release local anaesthetic formulation of ropivacaine, classified as a type 2.2 new drug, with potential for post-operative analgesia by subcutaneous infiltration and peripheral nerve blockade. This study aimed to validate the superior properties of CZ1S over ropivacaine hydrochloride injection and to evaluate the safety, tolerability, pharmacokinetic (PK) and pharmacodynamic (PD) profiles of a single dose of brachial plexus block with CZ1S in healthy Chinese adults.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!